Key result
A lipid metabolism-related risk signature based on CYP19A1 expression was identified as an independent prognostic factor for overall survival in patients with gastric cancer.
Why the study?
Altered lipid metabolism is linked to gastric cancer progression, but comprehensive analysis identifying critical lipid metabolic drivers to predict overall survival is not fully elucidated.
Does CYP19A1 expression predict overall survival and immune cell infiltration in gastric cancer patients?
Observational
Does CYP19A1 expression predict overall survival and immune cell infiltration in gastric cancer patients?
CYP19A1 is a potential independent prognostic biomarker and metabolic-targeted treatment strategy for gastric cancer.
Answers are grounded in this paper and cite their sources.
May support CYP19A1 signature for gastric cancer prognostication; leaves open prospective validation and therapeutic targeting.
Background: Altered lipid metabolism is associated with gastric cancer (GC) progression. Comprehensive analysis to identify critical lipid metabolic drivers for predicting overall survival (OS) is not fully elucidated in GC. Our study aim to explore a novel lipid metabolism-related prognostic marker for GC. Methods: Transcriptional status and clinical features were obtained from the TCGA-STAD database. The differentially expressed lipid metabolic genes and the risk prognostic model were developed by using bioinformatics and Cox regression analyses. ROC and Kaplan-Meier analysis were established to assess the performance of the risk predictive score model. GSE84437 dataset was used for external validation. Immunochemistry (IHC) was used to examine the expression of CYP19A1 in GC patients. Gene Set Enrichment Analysis (GSEA) was conducted to elucidate the underlying enriched mechanisms. TIMER and CIBERSORT analysis were performed to explore the relationship between CYP19A1 and immune microenvironment. Using the validation cohort, ROC curves indicate a good showing of our risk model. Based on the signature yielded a significant difference OS time between the low- and high-risk groups. Cox regression indicates that the signature is an independent prognostic variable. ROC curves present better and reliability predictive accuracy. The IHC data validate that high expression of CYP19A1 was found in GC tissues. GSEA analysis reveals that higher expression of CYP19A1 may significantly up-regulate genes involved in fatty acid metabolism and glycerolipid metabolism. CIBERSORT analysis suggests that CYP19A1 is related to the infiltration of multiple immune cells. Conclusion: CYP19A1 could be an independent prognostic factor and a novel metabolic-targeted treatment strategy for gastric cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted an observational in Gastric cancer. CYP19A1 expression (lipid metabolic-related signature) vs. Low expression / low-risk group was evaluated on Overall survival (OS). A lipid metabolism-related risk signature based on CYP19A1 expression was identified as an independent prognostic factor for overall survival in patients with gastric cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: